The reiteration of an Outperform rating and maintenance of a $10 price target by a reputable analyst like Luca Issi from RBC Capital could instill confidence among investors and potentially lead to a positive short-term impact on Allogene Therapeutics' stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.